Clinical economics review: Cost-effectiveness in the therapy of liver disease

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 1, 1997, Pages 61-68

  Neuberger, J ^a   Bryan, S ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; CIPROFLOXACIN; CYCLOSPORIN A; MALOTILATE; METHOTREXATE; NORFLOXACIN; PENICILLAMINE; PREDNISOLONE; TACROLIMUS; TERLIPRESSIN; THALIDOMIDE; URSODEOXYCHOLIC ACID;

ASCITES; BILIARY CIRRHOSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE COST; HUMAN; LIVER DISEASE; PERITONITIS; PRIORITY JOURNAL; REVIEW; SCLEROTHERAPY; VIRUS HEPATITIS;

EID: 0031026697     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.82254000.x     Document Type: Review

References (30)

1. Koff R, Seeff L. Economic modelling of treatment in chronic B and chronic hepatitis C: promises and limitations. Hepatology 1995; 22: 1880-2.
2. Cook G, Mulligan R, Sherlock S. Controlled trial of corticosteroid therapy in chronic active hepatitis. Q J Med 1971; 40: 159-85.
3. Eddleston A. Modern vaccines. Lancet 1990; 335: 1142-5.
4. Mitchison H, Palmer J, Bassendine M, et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis. J Hepatol 1992; 15: 336-44.
5. O'Donohue J, Williams R. Primary biliary cirrhosis. Q J Med 1996; 89: 5-13.
6. Lindor K, Dickson ER, Baldus W, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
7. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicentre double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
8. Poupon R, Poupon R, Balkau B, & The UDCA-PBC Study Group. Orsodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342-7.
9. Heathcote EJ, Lindon K, Poupon R, et al. Combined analysis of French, American and Canadian randomised controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1995; 108: 1082A. (Abstract.)
10. Carreno V, Bartolome J, Castillo I. Long-term effects of interferon therapy in chronic hepatitis B. BJ Hepatol 1994; 20: 431-5.
11. Dusheiko G, Roberts J. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995; 22: 1863-73.
12. Sheill A, Briggs A, Farrell GC. The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aus 1994; 160: 268-72.
13. Arroyo V, Gines P, Rodes J. Treatment of ascites in patients with cirrhosis of the liver. J Hepatol 1986; 2: 502-4.
14. Smart H, Triger D. A randomised, prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic resistant ascites. J Hepatol 1990; 10: 191-7.
15. Salerno F, Badalamenti S, Lorrenzano E, Moser P, Incerti P. Randomised comparative study of Haemaccel vs albumin infusion after total paracentesis in cirrhotic patients with intractable ascites. Hepatology 1991; 13: 707-13.
16. Fassio E, Terg R, Landeira G, et al. Paracentesis with Dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. J Hepatol 1992; 14: 310-6.
17. Sola R, Vila C, Andreu M, et al. Total paracentesis with Dextran-40 versus diuretics in the treatment of ascites in cirrhosis. J Hepatol 1994; 20: 282-8.
18. Cabrera J, Inglada L, Quintero E, et al. Large volume paracentesis and intravenous saline: effects on the renin angiotensin system. Hepatology 1991; 14: 1025-8.
19. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin in the management of patients with cirrhosis and ascites. Gastroenterology 1990; 98: 146-51.
20. Gines P, Tito L, Pares J, et al. Paracentesis versus paracentesis plus intravenous albumin in the treatment of ascites. J Hepatol 1986; 3: S23.
21. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent shunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-7.
22. Shiffman M, Jeffers L, Hoofnagle J, Tralka T. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Board. Hepatology 1992; 14: 1591-5.
23. McCormick P, Dick R, Burroughs A. Review article: the transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of portal hypertension. Aliment Pharmacol Ther 1994; 8: 273-82.
24. Pasha T, Kamath P. Shunt stenosis post TPIS: ultrasonography is the most cost-effective strategy. Gastroenterology 1996; 110: A1291. (Abstract.)
25. Singh N, Gayowski T, Yu V, Wagener M. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis - a randomised trial. Ann Intern Med 1995; 122: 595-8.
26. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind placebo controlled trial. Hepatology 1990; 12: 716-24.
27. Rolachon A. Cordier L, Bacq Y, et al. Ciprolloxacin and long-term prevention of spontaneous peritonitis: results of a prospective, controlled trial. Hepatology 1995; 22: 1171-4.
28. Bosch J, D'Amico G, Luca A, et al. Drug therapy for variceal bleeding. In: Bosch J, Groszmann R, eds. Portal Hypertension. Oxford: Blackwell Scientific Publications. 1995: 108-25.
29. Steigmann G, Goff J, Michalatz-Onody P, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding oesophageal varices. N Engl J Med 1992; 326: 1527-32.
30. Hashizuma M, Ohta M, Ueno K, et al. Endoscopic ligation of oesophageal varices significantly reduces adverse effects of injection sclerotherapy. Gastrointest Endosc 1993; 39: 123-27.